In summary, this scoping review identified a range of markers associated with breast cancer recurrence across three main modalities: clinical (e.g., CA 15.3, CEA, clinical stage), radiological (e.g., MD, METV, radiomic features), and histopathological (e.g., HER2, Ki-67, nuclear grade). This evidence concerns the gene ERBB2 and breast carcinoma.